Background and aims: There are concerns that incretin-based antidiabetic drugs – including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists – increase the risk of hospitalization for heart failure (HF). To further analyse this issue, we conducted a nested case-control study within a cohort of antidiabetic users in a real world setting. Methods and results: Within a cohort of 133,639 subjects with a first prescription of an antidiabetic drug (new-users) between 2010 and 2016 in Lombardy, Italy, and were followed-up to 2016, we identified 4057 subjects with a first hospitalization for HF and 80,450 controls matched on sex, age, and date of cohort-entry. The multivariate odds ratios (ORs) of HF in relation to current use of incretin-based drugs as compared to current use of two or more oral antidiabetics was 1.06 (95% confidence interval, CI, 0.83–1.35), with no evidence of a trend in risk with increasing duration of use. The corresponding ORs were 1.10 (95% CI 0.85–1.41) for DPP-4 inhibitors and 0.84 (95% CI 0.48–1.47) for GLP-1 receptor agonists. Estimates were consistent in various sensitivity analyses. Conclusions: This study indicates that incretin-based drugs are not associated with an increased risk of hospitalization for HF, thus providing further reassurance on the cardiovascular safety of these antidiabetic drugs in the clinical practice

Santucci, C., Franchi, M., Staszewsky, L., La Vecchia, C., Latini, R., Merlino, L., et al. (2018). Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. DIABETES RESEARCH AND CLINICAL PRACTICE, 146, 172-179 [10.1016/j.diabres.2018.10.006].

Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study

Franchi, M.
Secondo
;
Corrao, G.
Penultimo
;
2018

Abstract

Background and aims: There are concerns that incretin-based antidiabetic drugs – including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists – increase the risk of hospitalization for heart failure (HF). To further analyse this issue, we conducted a nested case-control study within a cohort of antidiabetic users in a real world setting. Methods and results: Within a cohort of 133,639 subjects with a first prescription of an antidiabetic drug (new-users) between 2010 and 2016 in Lombardy, Italy, and were followed-up to 2016, we identified 4057 subjects with a first hospitalization for HF and 80,450 controls matched on sex, age, and date of cohort-entry. The multivariate odds ratios (ORs) of HF in relation to current use of incretin-based drugs as compared to current use of two or more oral antidiabetics was 1.06 (95% confidence interval, CI, 0.83–1.35), with no evidence of a trend in risk with increasing duration of use. The corresponding ORs were 1.10 (95% CI 0.85–1.41) for DPP-4 inhibitors and 0.84 (95% CI 0.48–1.47) for GLP-1 receptor agonists. Estimates were consistent in various sensitivity analyses. Conclusions: This study indicates that incretin-based drugs are not associated with an increased risk of hospitalization for HF, thus providing further reassurance on the cardiovascular safety of these antidiabetic drugs in the clinical practice
Articolo in rivista - Articolo scientifico
Diabetes; Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide-1 receptor agonists; Heart failure; Incretin-based drugs; Pharmacoepidemiology; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
English
2018
146
172
179
none
Santucci, C., Franchi, M., Staszewsky, L., La Vecchia, C., Latini, R., Merlino, L., et al. (2018). Incretin-based drugs and hospitalization for heart failure in the clinical practice: A nested case-control study. DIABETES RESEARCH AND CLINICAL PRACTICE, 146, 172-179 [10.1016/j.diabres.2018.10.006].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/212781
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact